Clinical trials: Neuroendocrine Cancer
Prostate Cancer, Neuroendocrine Tumors
A Trial of BXCL701 and Pembrolizumab in Patients With mCRPC Either Small Cell Neuroendocrine Prostate Cancer or Adenocarcinoma Phenotype.
An open-label, multicenter, Phase 1b/2 study to identify the recommended Phase 2 dose and assess the efficacy and safety of BXCL701 administered orally, as monotherapy and in combination with PEMBRO, in patients with mCRPC.
- Conditions
- Prostate Cancer, Neuroendocrine Tumors, Small Cell Carcinoma
- Trial name
- NCT03910660
- Testing
- BXCL701 plus Pembrolizumab, BXCL701 monotherapy
- Where
- 12 sites in United States, United Kingdom
- Volunteers
- 98 people
- Sponsor
- BioXcel Therapeutics Inc
Unresectable Locally Advanced or Metastatic, Medullary Thyroid Carcinoma
Evaluate the Safety and Tolerability of Vandetanib in Japanese Patients With Medullary Thyroid Carcinoma
Open-label Study to Evaluate the Safety and Tolerability of Vandetanib 300 mg/day in Japanese Patients with Unresectable Locally Advanced or Metastatic Medullary Thyroid Carcinoma.
- Trial name
- NCT01661179
- Testing
- Vandetanib 300mg
- Where
- 4 sites in Japan
- Volunteers
- 14 people
- Sponsor
- Genzyme, a Sanofi Company
Melanoma, Malignant Metastatic Melanoma
Evaluating The Antitumor Activity Of MEDI-522 With Or Without Dacarbazine In Patients With Metastatic Melanoma
The primary objectives of this study are: To explore the antitumor activity of MEDI-522 ± DTIC in patients with metastatic melanoma. To determine the safety of MEDI-522 ± DTIC in this patient population.
- Trial name
- NCT00066196
- Testing
- MEDI--522, Integrin + Dacarbazine
- Where
- 25 sites in United States
- Volunteers
- 110 people
- Sponsor
- MedImmune LLC
Advanced Melanoma, Metastatic Melanoma
PH 1 Biomarker Study of Nivolumab and Ipilimumab and Nivolumab in Combination With Ipilimumab in Advanced Melanoma
The purpose of this study is to evaluate pharmacodynamic changes of Nivolumab and Nivolumab in combination with Ipilimumab treatment on the biomarkers measured in the peripheral blood and tumor tissues of subjects with advanced…
- Trial name
- PD-1 (NCT01621490)
- Testing
- Nivolumab, Ipilimumab
- Where
- 14 sites in United States, Netherlands and 1 more
- Volunteers
- 170 people
- Sponsor
- Bristol-Myers Squibb
BRAFV600E Melanoma Patients
Dabrafenib and Trametinib With Radiosurgery in Melanoma Brain Mets
The purpose of this study is to test the safety and find out what effects, good and/or bad, dabrafenib (a BRAF inhibitor) alone or dabrafenib when given in combination with gamma knife radiosurgery has on participants with a…
- Trial name
- NCT01721603
- Testing
- Dabrafenib, Gamma Knife Radiosurgery, Trametinib
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- University of California, San Francisco
Metastatic Malignant Neoplasm in the Liver, Pancreatic Neuroendocrine Tumor
Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors
This phase II trial studies the effect of capecitabine and temozolomide after surgery in treating patients with high-risk well-differentiated pancreatic neuroendocrine tumors.
- Conditions
- Metastatic Malignant Neoplasm in the Liver, Pancreatic Neuroendocrine Tumor, Stage I Pancreatic Neuroendocrine Tumor AJCC v8, Stage II Pancreatic Neuroendocrine Tumor AJCC v8
- Trial name
- NCT05040360
- Testing
- Capecitabine, Temozolomide
- Where
- 448 sites in United States, Mexico and 1 more
- Volunteers
- 141 people
- Sponsor
- SWOG Cancer Research Network
Uveal Melanoma
Morphological, Genetic and Tumour Microenvironment Characterisation in Uveal Melanoma
The objectives of the study are the morpho-phenotypic evaluation of uveal melanoma and to identify molecular prognostic factors that may be correlated with disease severity, tumour progression and response to treatment.
- Trial name
- MicroGenUM (NCT05889481)
- Testing
- cytogenetic analysis on tumour tissue, Digital Pathology
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Melanoma (Skin)
Vaccine Therapy in Treating Patients With Stage IV Melanoma
Randomized phase I trial to study the effectiveness of vaccine therapy in treating patients who have stage IV melanoma. Vaccines may make the body build an immune response to kill tumor cells.
- Trial name
- NCT00003665
- Testing
- dendritic cell-MART-1 peptide vaccine, gp100 antigen, therapeutic tumor infiltrating lymphocytes
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Unresectable Melanoma, Metastatic Melanoma
Mirdametinib in Patients With Advanced NF1-mutant Melanoma
The goal of this clinical trial is to evaluate clinical efficacy of mirdametinib in patients with advanced NF1-mutant melanoma whose disease has progressed while on or after previous immunotherapy.
- Trial name
- NCT07237100
- Testing
- Mirdametinib
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Kevin Kim, MD
Solid Tumor, Adult, Non-Hodgkin Lymphoma, Adult
A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers
The objective of study IOA-244-101 is to determine whether IOA-244 is safe and tolerable in cancer patients (Part A). In addition, the study will assess whether IOA-244 can increase the anti-tumour immune response in patients…
- Conditions
- Solid Tumor, Adult, Non-Hodgkin Lymphoma, Adult, NSCLC, Myelofibrosis
- Trial name
- NCT04328844
- Testing
- IOA-244, Avelumab Injection, Pemetrexed
- Where
- 3 sites in Italy, United Kingdom
- Volunteers
- 210 people
- Sponsor
- iOnctura
CD27 Expressing B-cell Malignancies for Example Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia
A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers
This is a study of CDX-1127, a therapy that targets the immune system and may act to promote anti-cancer effects. The study enrolls patients with hematologic cancers (certain leukemias and lymphomas), as well as patients with…
- Conditions
- CD27 Expressing B-cell Malignancies for Example Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Marginal Zone B Cell Lymphoma)
- Trial name
- NCT01460134
- Testing
- CDX-1127
- Where
- 10 sites in United States
- Volunteers
- 90 people
- Sponsor
- Celldex Therapeutics
HCC - Hepatocellular Carcinoma, CRC (Colorectal Cancer)
ENPP1/cGAS (EG) and FAP Expression Profiles in Solid Tumors: An Immunohistochemical Study in a Vietnamese Cohort
This Vietnam-based observational study examines ecto-nucleotide pyrophosphatase/phosphodiesterase 1/cyclic GMP-AMP synthase (ENPP1/cGAS) protein and stromal fibroblast activation protein (FAP) expression in multiple solid tumor…
- Conditions
- HCC - Hepatocellular Carcinoma, CRC (Colorectal Cancer), Gastric Carcinoma, Breast Cancer
- Trial name
- NCT07808164
- Testing
- IHC analysis for ENPP1, cGAS, and FAP expression
- Where
- 2 sites in Vietnam
- Volunteers
- 162 people
- Sponsor
- Tam Anh Research Institute
Neuroendocrine Tumors
Pasireotide, Everolimus and Selective Internal Radioembolization Therapy for Unresectable Hepatic Metastases
The purpose of this study is to see the safety and activity of using pasireotide, everolimus and radioembolization (Selective Internal Radioembolization Therapy-SIRT) in the treatment of neuroendocrine tumors (carcinoid) that has…
- Trial name
- NCT01469572
- Testing
- Pasireotide, Sir-sphere Radioembolization, Everolimus
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Emory University
Neuroendocrine Carcinoma
Combination of Bevacizumab, Pertuzumab, and Sandostatin for Adv. Neuroendocrine Cancers
The purpose of this Phase II trial will be to define the activity of a VEGF inhibitor bevacizumab, HER1/HER2 inhibitor pertuzumab, and sandostatin for patients with advanced neuroendocrine cancers.
- Trial name
- NCT01121939
- Testing
- Bevacizumab, Pertuzumab, Sandostatin LAR® Depot
- Where
- 9 sites in United States
- Volunteers
- 43 people
- Sponsor
- SCRI Development Innovations, LLC
Neuroendocrine Tumors,Gastroenteropancreatic
Cabozantinib and Lanreotide as Treatment for Gastroenteropancreatic Neuroendocrine Tumors
This is an Open-Label Phase I/II Study of daily cabozantinib plus lanreotide every 4 w eeks to treat advanced G1-2 gastroentero-pancreatic neuroendocrine tumor (GEP-NET) patients who failed to one line or more than one line of…
- Trial name
- NCT05048901
- Testing
- Cabozantinib, Lanreotide
- Where
- 11 sites in Taiwan
- Volunteers
- 49 people
- Sponsor
- National Health Research Institutes, Taiwan
Uveal Melanoma
Treatment Of Radiation Retinopathy Trial
The purpose of this study is to demonstrate a statistically significant improvement of visual acuity after treatment using either Lucentis® or Triamcinolone® compared to no treatment, in patients with radiation retinopathy.
- Trial name
- TORR (NCT00811200)
- Testing
- ranibizumab, triamcinolone acetonide
- Volunteers
- 220 people
- Sponsor
- Leiden University Medical Center
Melanoma
Study of TLR9 Agonist Vidutolimod (CMP-001) in Combination With Nivolumab vs. Nivolumab
The main goal of this research study is to determine how nivolumab and nivolumab/Vidutolimod (CMP-001) combination affect the likelihood of destroying melanoma involving lymph node and/or in-transit/satellite areas.
- Trial name
- NCT04401995
- Testing
- Vidutolimod (CMP-001), Nivolumab, [18F]F-AraG PET/CT
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Diwakar Davar
Solid Tumor
Study of IMF-001 in Patients With Malignancies Expressing NY-ESO-1
The purpose of this study is assess the safety of administering repeated doses of IMF-001, a vaccine, to patients with solid tumors that express NY-ESO-1 antigen.
- Trial name
- NCT01234012
- Testing
- IMF-001
- Where
- 2 sites in United States
- Volunteers
- 23 people
- Sponsor
- ImmunoFrontier, Inc.
Melanoma (Skin)
A Personalized NeoAntigen Cancer Vaccine Combined With Anti-PD-1 in Melanoma
This study assessed the safety and efficacy of individualized new antigen cancer vaccine combined with Programmed Cell Death Protein 1（PD1） inhibitor Toripalimab in the treatment of metastatic cutaneous melanoma.
- Trial name
- NCT04072900
- Testing
- Peptide, Anti-PD-1, rhGM-CSF
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Xiangya Hospital of Central South University
Metastatic Uveal Melanoma
Efficacy Study of Pembrolizumab With Entinostat to Treat Metastatic Melanoma of the Eye
The purpose of this study is to see if the combination of entinostat and pembrolizumab can be an effective treatment for patients with melanoma of the eye (uveal melanoma) that has spread to other sites of the body (metastatic…
- Trial name
- PEMDAC (NCT02697630)
- Testing
- Pembrolizumab, Entinostat
- Where
- Sweden
- Volunteers
- 29 people
- Sponsor
- Vastra Gotaland Region